Executive Withholds 7,000 Shares of Golf Stock for Tax Obligations

Truist Securities raised its price target for Callaway Golf (NYSE:ELY) to $20.00 from $19.00, citing self-help factors like SKU rationalization and store closures. The stock is up 64% over the past year. Callaway reported Q2 2026 earnings of $0.39 per share, beating estimates, with revenue of $612.2 million and a 36% increase in adjusted EBITDA.

Callaway Golf Co (CALY) filed an SEC Form 8-K — Results of Operations and Financial Condition. CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS Second Quarter Net Sales (+2%), GAAP Net Income from Continuing Operations (+67%) and Adjusted EBITDA (+36%) Raises Full-Year Guidance HIGHLIGHTS • Q2 GAAP and Non-GAAP Gross Margin increased 620 basis points and 460 bas

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

KeyBanc upgraded Generac (GNRC) to Overweight with a $280 price target, citing confidence in its $8B Amazon deal. GNRC stock is up 62% YTD. Analysts debate capacity ramp-up, but management is confident. Other firms also raised targets, while some lowered them due to execution concerns.

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

Biohaven (BHVN) has licensed IgG degraders to Ono Pharma for Japan and select Asian regions. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. The agreement marks a strategic partnership and late-stage pipeline update for Biohaven's immunology platform.